

Supplementary Table 3. Correlations between change in average E/e' and changes in other clinical variables among participants in the dapagliflozin group ($n=25$)

Change in cardiometabolic parameter	Change in average E/e'	
	Crude r	P value
Body weight, kg	0.117	0.579
WC, cm	-0.240	0.247
Systolic BP, mm Hg	-0.076	0.719
Diastolic BP, mm Hg	-0.049	0.815
Total daily insulin dose, units	0.066	0.755
FG, mmol/L	0.222	0.287
HbA1c, %	0.297	0.149
eGFR, mL/min/1.73 m ²	0.012	0.954
HDL-C, mmol/L	0.262	0.205
LDL-C, mmol/L	0.119	0.570
TG ^a , mmol/L	-0.085	0.686
ALT ^a , U/L	0.292	0.156
AST ^a , U/L	0.261	0.207
CAP, dB/m	-0.104	0.620
LS ^a , kPa	0.241	0.247
HDL-CEC, %	-0.405	0.045
hsCRP ^a , mg/L	-0.294	0.153
BHB ^a , μmol/L	0.015	0.944
FFA ^a , μmol/L	0.016	0.938

WC, waist circumference; BP, blood pressure; FG, fasting glucose; HbA1c, glycosylated hemoglobin; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAP, controlled attenuation parameter; LS, liver stiffness; CEC, cholesterol efflux capacity; hsCRP, high sensitivity C-reactive protein; BHB, β-hydroxybutyrate; FFA, free fatty acid.

^aLog-transformed before analysis.